Abivax develops medicines that alter the body's natural immune system mechanisms.
Abivax was founded in 2013 by Philippe Pouletty.
1282 health care and life sciences companies are in the directory, 165 of them in the same 101-250 employee range and 184 based in European Union (EU).
Abivax may be growing as it is listed among key companies in the Inflammatory Bowel Disease market, which is projected to exhibit significant growth by 2032. This inclusion suggests that Abivax is actively involved in a market with a positive growth trajectory. Furthermore, the company's association with the development of therapies in a growing market indicates ongoing research and development efforts. The market's expected growth could potentially lead to increased demand for Abivax's therapeutic solutions, contributing to the company's financial growth and expansion.
“Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA.” abivax.com
Abivax has a 101-250 person team and operates in biotechnology, listed under European Union (EU), and has been around since 2013. Its website drew about 615 visits in the latest month measured and its founder is Philippe Pouletty.
101-250 employees · aveooncology.com
51-100 employees · 4basebio.com
101-250 employees · adimab.com
51-100 employees · acrivon.com
51-100 employees · 1859.ai
11-50 employees · a-biodesign.com
501-1,000 employees · adaptivebiotech.com
11-50 employees · acernatec.com
11-50 employees · advancells.com
11-50 employees · alxoncology.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.